Cyclerion Therapeutics, Inc.
CYCN
$3.43
$0.4213.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.00M | 194.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00M | 194.00K | -- | -- | -- |
| Cost of Revenue | 149.00K | 149.00K | 149.00K | 383.00K | 911.00K |
| Gross Profit | 1.85M | 45.00K | -149.00K | -383.00K | -911.00K |
| SG&A Expenses | 5.34M | 6.07M | 6.96M | 7.20M | 8.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.63M | 6.12M | 7.51M | 7.99M | 9.65M |
| Operating Income | -3.63M | -5.93M | -7.51M | -7.99M | -9.65M |
| Income Before Tax | -3.06M | -5.28M | -10.47M | -10.95M | -12.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.06 | -5.28 | -10.47 | -10.95 | -12.59 |
| Earnings from Discontinued Operations | -- | 0.00 | 13.47M | 11.10M | 7.33M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.06M | -5.28M | 3.01M | 149.00K | -5.26M |
| EBIT | -3.63M | -5.93M | -7.51M | -7.99M | -9.65M |
| EBITDA | -- | -1.78M | -4.47M | -6.32M | -9.58M |
| EPS Basic | -1.22 | -2.13 | 1.26 | -0.04 | -2.62 |
| Normalized Basic EPS | -0.76 | -1.31 | -1.80 | -1.97 | -2.50 |
| EPS Diluted | -1.23 | -2.14 | 1.26 | -0.04 | -2.62 |
| Normalized Diluted EPS | -0.76 | -1.31 | -1.80 | -1.97 | -2.50 |
| Average Basic Shares Outstanding | 10.07M | 9.87M | 9.78M | 9.55M | 9.23M |
| Average Diluted Shares Outstanding | 10.07M | 9.87M | 9.78M | 9.55M | 9.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |